Ipamorelin Complete Guide: The Cleanest GH Secretagogue and Why It Earned That Reputation (2026)

Ipamorelin: The Cleanest Growth Hormone Secretagogue Available for Research

Ipamorelin is a synthetic pentapeptide that selectively stimulates growth hormone release without triggering cortisol, ACTH, prolactin, or sex hormone dysregulation. Developed by Novo Nordisk and characterised in landmark 1998 research, it remains the gold standard among GH secretagogues for researchers prioritising a clean hormonal profile.

Affiliate disclosure: This post contains affiliate links to research-grade peptide suppliers. If you purchase through those links, Underground Biohacking may earn a commission at no extra cost to you. We only link to suppliers we have independently reviewed for purity and documentation standards. View current ipamorelin stock at RealPeptides.

What Is Ipamorelin and Why Does Selectivity Matter?

Ipamorelin (NNC 26-0161) is a pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It was the first ghrelin-receptor agonist demonstrated to release GH with selectivity comparable to endogenous GHRH rather than the broader hormonal activation profile of earlier secretagogues like GHRP-6 or GHRP-2.

The distinction matters enormously in practice. GHRP-6 and GHRP-2 release GH effectively, but they co-stimulate ACTH and cortisol in a dose-dependent fashion. Cortisol is catabolic, suppresses immune function, and counteracts several goals GH secretagogues are typically researched for. Ipamorelin sidesteps this entirely. The foundational Novo Nordisk characterisation study found that ipamorelin did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation, even at doses more than 200-fold above the ED50. Ankersen et al. 1998

That single pharmacological fact is why ipamorelin earned the label "cleanest" secretagogue. It is not marketing language. It is the mechanistic outcome of its receptor binding profile.

Mechanism of Action: How Ipamorelin Drives GH Pulses

Ipamorelin binds the growth hormone secretagogue receptor 1a (GHS-R1a), the same receptor activated by endogenous ghrelin. GHS-R1a sits on somatotroph cells in the anterior pituitary. When ipamorelin binds this receptor, it drives a rapid, pulsatile GH release that closely mirrors what happens during natural slow-wave sleep.

The kinetics in human volunteers are well-characterised. A Phase I pharmacokinetic-pharmacodynamic study in eight healthy male volunteers documented a GH peak at approximately 0.67 hours post-administration, followed by exponential decline to negligible GH concentrations, with a terminal half-life of roughly two hours and clearance of 0.078 L/h/kg. Raun et al. 1999

Critically, the GH pulse returns to baseline within three to four hours. This pulsatile profile is physiologically significant: it avoids the sustained, supraphysiological GH elevation associated with receptor downregulation and the adverse effect profile of exogenous recombinant GH. For researchers comparing ipamorelin against exogenous GH, see our breakdown of growth hormone secretagogues vs exogenous HGH.

Ipamorelin also does not significantly affect prolactin, FSH, LH, or TSH plasma levels. Ankersen et al. 1998 This specificity means the hypothalamic-pituitary-gonadal axis is not perturbed, which is a meaningful advantage in research contexts where compound interactions are being studied.

Ipamorelin vs GHRP-6 and GHRP-2: A Direct Comparison

The competitive landscape among GH-releasing peptides is often misunderstood. Here is what the evidence actually shows:

GHRP-6

GHRP-6 has comparable GH-releasing potency to ipamorelin in animal models. The critical difference is the side-effect architecture. GHRP-6 elevates cortisol and prolactin significantly at research doses, and it is a potent appetite stimulant via hypothalamic NPY release. For recovery and body composition research, a cortisol spike concurrent with GH release is counterproductive. Ipamorelin avoids this entirely. For a detailed mechanistic comparison, see our article on GHRP-6 vs ipamorelin selectivity and protocol design.

GHRP-2

GHRP-2 offers higher GH release potency than ipamorelin at equivalent doses but delivers lower efficacy (maximum achievable GH elevation). It also produces significant cortisol and prolactin co-release. The higher cortisol burden makes it unsuitable for most recovery-focused research protocols.

Summary Table

Dosing Protocols and the Dosage Calculator

The following dosing information is drawn from published clinical data and documented research protocols. It is presented for educational purposes. Always work with a qualified clinician before making changes to your health protocol.

Dosage Reference Calculator

Use the table below to identify the typical dosing range based on body weight and injection frequency observed in published protocols and research-use documentation. This is not a personalised medical recommendation.

Note: The Phase 2 clinical trial used 0.03 mg/kg twice daily IV (approximately 2.1 mg/day for an 70 kg subject) in a hospital postoperative setting. Popescu et al. 2014 Subcutaneous research protocols in community documentation use substantially lower fixed doses (100–300 µg). These are not equivalent contexts.

Timing Protocols

Insulin suppresses GH secretion directly. Maximum GH response from ipamorelin requires a fasted state at injection. The standard guidance in published protocols is: inject at least two hours after the last meal, then wait a minimum of 30 minutes before eating. Bedtime dosing in a fasted state is considered optimal by most researchers, as it aligns the synthetic GH pulse with the natural nocturnal GH surge during slow-wave sleep.

Anecdotal note (community documentation, not primary research): Most users in online peptide research communities report 150–200 µg subcutaneous injection nightly as the most common starting point, with dose titration upward based on tolerance over four to six weeks. This is anecdote, not clinical evidence.

Duration Frameworks

Research protocols documented in the community most commonly reference 12 weeks on with a four-week washout. This approach is designed to avoid GHS-R1a downregulation from chronic stimulation. There is no human clinical data validating this specific on/off framework, and it represents community consensus rather than evidence-based guidance.

The CJC-1295 and Ipamorelin Stack

Ipamorelin is most commonly researched in combination with CJC-1295 (a GHRH analogue). The rationale is mechanistic: ipamorelin and CJC-1295 act at different nodes of the hypothalamic-pituitary axis. CJC-1295 occupies the GHRH receptor and sustains a permissive hormonal environment; ipamorelin then triggers the acute GH spike via GHS-R1a. The combination produces additive GH output that exceeds either compound alone.

CJC-1295 with DAC (Drug Affinity Complex) has a half-life of six to eight days, allowing once or twice-weekly administration. CJC-1295 without DAC (sometimes called Modified GRF 1-29) has a half-life of 30 minutes and is typically dosed alongside ipamorelin. For a full breakdown of protocol design for this combination, see our CJC-1295 and ipamorelin synergistic protocol guide.

A comprehensive review of GH secretagogue pharmacology positions ipamorelin as a selective GHS-R1a agonist with the most favourable hormone-specificity profile among the GHRP-class compounds, and notes its utility in combination protocols precisely because of this selectivity. Sigalos and Pastuszak 2020

Bone Health and Recovery Research

The recovery and structural biology data on ipamorelin are among the more compelling aspects of its research profile, and they are underreported in most popular summaries.

Bone Mineral Content

A 15-day dose-dependent study in adult female rats demonstrated that ipamorelin increased longitudinal bone growth rate from 42 µm/day in vehicle-treated controls to 52 µm/day at the highest dose, with dose-dependent body weight increases but without affecting IGF-I levels or standard bone markers. Svensson et al. 1999

A subsequent 12-week study in Sprague-Dawley rats using continuous subcutaneous delivery (0.5 mg/kg/day via osmotic minipumps) showed ipamorelin increased total tibial and vertebral bone mineral content as measured by DXA, with tibial area bone mineral density increased. Svensson et al. 2000

Counteracting Glucocorticoid-Induced Catabolism

Perhaps the most striking preclinical finding is the ability of ipamorelin to counteract glucocorticoid-induced bone and muscle catabolism. In a three-month study in eight-month-old female rats receiving methylprednisolone, co-administration of ipamorelin (100 µg/kg three times daily subcutaneous) increased maximum tetanic tension four-fold versus the glucocorticoid-alone group and normalised bone formation parameters. Johansen et al. 2001

This is preclinical data and cannot be directly extrapolated to human physiology. However, the magnitude of the protective effect against induced catabolism is notable and provides a mechanistic basis for investigating ipamorelin in contexts where GH/IGF-1 axis support may offset catabolic pressures.

Gastrointestinal Motility Research

The GHS-R1a receptor is expressed throughout the gastrointestinal tract, not only in the pituitary. Ipamorelin's ghrelin-mimetic action therefore extends to GI motility. A rodent model of postoperative ileus demonstrated that ipamorelin dose-dependently accelerated gastric emptying via ghrelin receptor-mediated stimulation of gastric contractility, with the fraction of meal retained dropping from 78% to 52% at the highest dose tested. Greenwood-Van Meerveld et al. 2016

This is the mechanistic basis for the Phase 2 clinical trial that investigated ipamorelin in human postoperative ileus following bowel resection. The double-blind, placebo-controlled multicentre trial (n=114) found that ipamorelin 0.03 mg/kg twice daily IV for up to seven days was well tolerated, with no serious adverse events, though it did not meet its primary efficacy endpoint in this specific post-surgical population. Popescu et al. 2014

The clinical GI safety data from this trial are the most robust human safety evidence available for ipamorelin, covering up to seven days of repeated IV dosing in a vulnerable post-surgical population.

Safety Profile: What the Data Actually Shows

The ipamorelin safety data divides cleanly into what is known and what is extrapolated.

What Is Known

• Phase 1 PK/PD study: no serious adverse events at dose escalation from 0.003 to 0.1 mg/kg IV in healthy male volunteers. Raun et al. 1999
• Phase 2 RCT: no serious adverse events over seven days at 0.03 mg/kg twice daily IV in n=114 post-surgical patients. Popescu et al. 2014
• No prolactin, FSH, LH, or TSH elevation at research doses. Ankersen et al. 1998
• Cortisol elevation equivalent to GHRH stimulus only, not exceeding physiological range even at supramaximal doses.

What Is Reported but Not Formally Studied

• Headache, fatigue, and joint discomfort at higher subcutaneous doses (community reports; resolve with dose reduction).
• Transient water retention in the early weeks of use (mechanism: GH-driven renal sodium retention).
• Mild appetite changes, particularly at higher doses.

Theoretical Risks Requiring Context

Questions about acromegaly risk arise with any GH-stimulating compound. Acromegaly from endogenous GH elevation requires chronically sustained, pharmacologically elevated GH output over years. Ipamorelin's pulsatile, short-duration profile, with GH returning to baseline within three to four hours, represents a fundamentally different exposure pattern from continuous GH infusion. Current preclinical and human safety data do not support significant acromegaly risk at standard research protocols. However, periodic IGF-1 monitoring is prudent with any GH-axis intervention, and medical supervision is essential. Always work with a qualified clinician before making changes to your health protocol.

Ipamorelin is contraindicated in active malignancy (GH is mitogenic), uncontrolled diabetes (GH is insulin-antagonistic), severe cardiovascular disease, and in WADA-governed athletes (GHS compounds are prohibited in competition).

Regulatory Status (May 2026)

Ipamorelin is not FDA-approved for human therapeutic use. As of May 2026, it remains prohibited for compounding under FDA 503A and 503B frameworks following the Pharmacy Compounding Advisory Committee (PCAC) review process. This means it cannot be legally dispensed by compounding pharmacies in the United States under current rules.

Regulatory status in other jurisdictions varies. Users should verify the legal status of ipamorelin in their specific jurisdiction before sourcing or researching with this compound. Obtain products only from suppliers who provide full certificates of analysis and third-party purity documentation.

Research-grade ipamorelin for non-clinical laboratory use operates under different frameworks. RealPeptides supplies research-grade ipamorelin with COA documentation for qualified researchers.

Who Is Ipamorelin Research Most Relevant For?

Based on the published mechanism and available data, ipamorelin research is most relevant for investigators examining:

• GH/IGF-1 axis modulation without cortisol co-elevation, where clean hormonal selectivity is a design requirement.
• Bone mineral content and structural recovery following glucocorticoid exposure or bone injury.
• GI motility mechanisms, particularly in postoperative or dysmotility contexts.
• Body composition interventions in hypogonadal or age-related GH-decline models, often in combination with CJC-1295.

A 2020 clinical review positioned ipamorelin specifically in the context of body composition management in hypogonadal males, noting its selectivity at GHS-R1a and its gastrointestinal effects via the same receptor class on GI tract tissue. Sigalos and Pastuszak 2020

Bibliography

1. Ankersen M, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PMID 9849822
2. Raun K, et al. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in Human Volunteers. J Pharmacol Exp Ther. 1999. PMID 10496658
3. Svensson J, et al. Ipamorelin induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999. PMID 10373343
4. Svensson J, et al. GH secretagogues increase bone mineral content in adult female rats. J Bone Miner Res. 2000. PMID 10828840
5. Johansen PB, et al. Ipamorelin counteracts glucocorticoid-induced decrease in bone formation. Growth Horm IGF Res. 2001. PMID 11735244
6. Popescu I, et al. Ipamorelin for management of postoperative ileus in bowel resection patients. Dig Dis Sci. 2014. PMID 25331030
7. Greenwood-Van Meerveld B, et al. Efficacy of ipamorelin on gastric dysmotility in postoperative ileus. J Cachexia Sarcopenia Muscle. 2016. PMC4863553
8. Sigalos JT, Pastuszak AW. Growth hormone secretagogues: history, mechanism of action, and clinical development. Sex Med Rev. 2020. DOI 10.1002/rco2.9
9. Sigalos JT, Pastuszak AW. Beyond the androgen receptor: GH secretagogues in hypogonadal males. Ther Adv Urol. 2020. PMC7108996

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.